Slide 1: FY26 Results Overview
rsonal use only ATOMO DIAGNOSTICS FY26 RESULTS OVERVIEW 24 SEPTEMBER 2026
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on The information presented in this presentation is subject to change without notice and Atomo does information available as at the date of this presentation. The information in this presentation is not have
Slide 3: Atomo Diagnostics - FY26 in Review
ATOMO DIAGNOSTICS - FY26 IN REVIEW ASX: AT1 Transitioning to sustainable revenue growth with an expanding new product pipeline Financial Highlights Business Highlights rsonal use only • Revenue growth of 41% bringing total revenue for the • Strong growth in HIV franchise of 21% to $2.8 million FY26
Slide 4: New Chapter for Atomo – From Foundation to Global Scale
NEW CHAPTER FOR ATOMO – FROM FOUNDATION TO GLOBAL SCALE Passing the baton from founder leadership to the next phase of commercial growth • Building on 15 years of innovation and execution under founder and long-standing CEO rsonal use only John Kelly • A seamless leadership transition designed to pr
Slide 5: Reflections on FY26
REFLECTIONS ON FY26 FY26 established the foundation for Atomo's next phase of value creation Accelerating growth: 41% FY26 revenue growth, reflecting strong momentum across the business rsonal use only Improving economics: Continued improvement in EBITDA (+39% YOY) as scale, mix and operational disc
Slide 6: Who Is Atomo and What Do We Do?
WHO IS ATOMO AND WHAT DO WE DO? Diagnostic company with a growing portfolio of patented rapid tests with proven superior usability, reliability, and performance WHO IS ATOMO? WHAT BUSINESSES DO WE HAVE? rsonal use only Atomo Point of Care Test (POCT) Diagnostic Products: • We are a commercial stage
Slide 7: Atomo's Own Diagnostic Product Pipeline
ATOMO’S OWN DIAGNOSTIC PRODUCT PIPELINE ASX: AT1 ASX: AT1 Commercial-stage diagnostic products company with a growing a portfolio of innovative point-of-care rapid tests for global markets Product Indication Feasibility Development Validation Clinical Trials Regulatory Approvals Commercial Launch TG
Slide 8: Partner Portfolio Updates
PARTNER PORTFOLIO UPDATES ASX: AT1 ASX: A1 Expanding sales from attractive OEM business with products ranging from launched to new ones entering the pipeline Ferritin – New Product Opportunity rsonal use only • Atomo has partnered with Chromacare to develop a rapid test for measuring iron levels, wi
Slide 9: FY26 – Revenue Summary
FY26 – REVENUE SUMMARY Strong sales growth across core activities in HIV Tests and Pascal OEM Revenue YoY Growth rsonal use only 3.00 Revenue growth across core activities 2.50 • HIV Growth 21% YoY, totaling $2.8 million 2.00 • OEM Growth 209% YoY, totaling $2.2 million • Overall total revenue* grow
Slide 10: HIV Business Activity
HIV BUSINESS ACTIVITY ASX: AT1 Continued push on growing HIV sales is paying off in 21% YOY growth in HIV sales Australian Pharmacy Growing Momentum International HIV Business • 196 pharmacies active in Australia Significant growth underway across European and LMIC markets rsonal use only • Target t
Slide 11: Active Syphilis – Advancing Through the Pipeline
ACTIVE SYPHILIS – ADVANCING THROUGH THE PIPELINE ASX: AT1 Successful completion of product development preparing for clinical trials in early CY27 Addressing significant unmet clinical and market needs Established demand via existing HIV channels • no existing rapid test can reliably distinguish act
Slide 12: ALT Liver Test – Enters the Development Pipeline
ALT LIVER TEST – ENTERS THE DEVELOPMENT PIPELINE Unique, large product opportunity for detecting liver damage rsonal use only Commercial pathway: Confirming priority use case for clinical-trials and doctor prescribed at-home liver Partner development: Engage with Australian monitoring clinical KOL’s
Slide 13: FebriDx – FY26 Highlights
FEBRIDx – FY26 HIGHLIGHTS 2026 and future revenue growth driven by Lumos Diagnostics CLIA waiver, sales focus, and distribution partnership • Atomo received FY26 orders for FebriDx totaling ~A$1.9m, representing a nine- rsonal use only fold increase in Pascal FebriDx orders when compared to FY25 • L
Slide 14: Chromacare – Ferritin Opportunity
CHROMACARE – FERRITIN OPPORTUNITY Another high value product targeted to the professional use, decentralised testing market Rapid Test to screen for Iron Deficiency in Point-of-Care rsonal use only Other Tests in active development • Atomo has partnered with Canadian company Chromacare on a rapid te
Slide 15: UK Client – Exciting New POCT Product Category
UK CLIENT – EXCITING NEW POCT PRODUCT CATEGORY Successful completion of manufacture of products for feasibility study UK Customer • Atomo is partnering with a UK company on a novel rapid test that rsonal use only addresses a large unmet clinical need in professional settings • 20,000 Pascal units or
Slide 16: FY26 Operational Update
FY26 OPERATIONAL UPDATE ASX: AT1 Execution on important steps to increase resilient capacity and improve gross margins Operational expansion initiated to support the growth of Atomo Diagnostic Products rsonal use only and OEM Pascal units • Increased production capacity and improved margins on suppl
Slide 17: Strategic Initiatives in FY27 and Beyond
STRATEGIC INITIATIVES in FY27 AND BEYOND Establish Atomo as a growing diagnostic company with a robust product pipeline Increasing Focus on New Atomo Products: Successfully finish development and launch Active Syphilis and Liver ALT marker while completing feasibility on additional pipeline products
Slide 18: FY 2026 Financials
rsonal use only FY 2026 FINANCIALS
Slide 19: FY26 Profit & Loss
FY26 PROFIT & LOSS Strong revenue growth and improving EBITDA while investing in innovative R&D development and pipeline FY26 FY25 • Revenue up 41%, driven by strong volume demand across HIV rsonal use only AUD (%) ($m) ($m) Global Health Market Revenue 5.33 3.79 41% • Gross margin lower due to prod
Slide 20: FY26 Balance Sheet
FY26 BALANCE SHEET Finishing the year with a solid cash position and no debt FY26 FY25 AUD rsonal use only ($m) ($m) • Cash and cash equivalents of $3.71m at 30 June 2026, and remaining Cash and cash equivalents 3.71 3.22 debt free Trade and other receivables 3.22 1.69 • During the year, the Atomo c
Slide 21: FY26 Cashflow
FY26 CASHFLOW Strong cash generation from sales, grants, and fundraising activities 16.00 • Total Cash receipts: $10.2m • ~$4.6m from customer receipts rsonal use only 14.00 • $875k from R&D tax rebate • $660k from CRC-P grant for Syphilis test 12.00 development 10.00 • ~4m from capital raised durin
Slide 22: Financial Summary
FINANCIAL SUMMARY ASX: AT1 FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA ✓ Capital focus on new test portfolio ✓ Atomo is seeing strong momentum in its established revenue development / commercialisation – Syphilis and channels including HIV Test
Slide 23: FY26: Year of Transition
FY26: YEAR OF TRANSITION Building a platform for sustainable growth Strong revenue momentum: FY26 revenue growth of 41%, demonstrates increasing demand across Atomo's core business lines and emerging opportunities rsonal use only Improving operating leverage: EBITDA performance continued to improve
Slide 24: Strategy Update and FY26 Full Year Investor Webinar
Atomo Strategy Update and FY26 Full Year Investor Webinar Presentation : AT1 Atomo Diagnostics Limited will hold its Strategy Update and FY26 Full Year Investor webinar on rsonal use only Thursday 24th September 2026 at 11:00 AM. To access Atomo’s Investor Hub please scan the QR code. For further in